Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2017 Filed Mar 3, 2017 00:21 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionDeferred Stock Units · Derivative | 3,721 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005434 · doc4.xml · derivative · entry 4 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,722 Underlying: Common Stock · 3,721 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:21 UTC |
Carruthers WendySVP, Human Resources
|
Tax withholdingCommon Stock | 10,873 | $24.55 | $266,932.15 |
DisclosureSEC source: 0001225208-17-005434 · doc4.xml · nonDerivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,686 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:21 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 3,721 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005434 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:21 UTC |
Carruthers WendySVP, Human Resources
|
GrantCommon Stock | 24,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005434 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,838 F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2016 and was subject to the completion of the concurrent three-year individual service period. On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:17 UTC |
Dawkins Keith DEVP, Global Chief Med. Off.
|
GrantPerformance Share Units · Derivative | 9,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005433 · doc4.xml · derivative · entry 6 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,923 Underlying: Common Stock · 9,923 shares Expires 2018-12-31 F6 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F7 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will be prorated and released following retirement. F7 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will be prorated and released following retirement. F7 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will be prorated and released following retirement. F7 · balance_after: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will be prorated and released following retirement. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:17 UTC |
Dawkins Keith DEVP, Global Chief Med. Off.
|
Exercise / conversionDeferred Stock Units · Derivative | 4,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005433 · doc4.xml · derivative · entry 5 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,736 Underlying: Common Stock · 4,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F5 · balance_after: Reflects multiple DSU awards with independent vesting schedules. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:17 UTC |
Dawkins Keith DEVP, Global Chief Med. Off.
|
SaleCommon Stock | 30,000 | $24.64 | $739,134.00 |
DisclosureSEC source: 0001225208-17-005433 · doc4.xml · nonDerivative · entry 4 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,165 F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.625 to $24.68, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:17 UTC |
Dawkins Keith DEVP, Global Chief Med. Off.
|
Tax withholdingCommon Stock | 11,955 | $24.55 | $293,495.25 |
DisclosureSEC source: 0001225208-17-005433 · doc4.xml · nonDerivative · entry 3 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,165 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:17 UTC |
Dawkins Keith DEVP, Global Chief Med. Off.
|
Exercise / conversionCommon Stock | 4,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005433 · doc4.xml · nonDerivative · entry 2 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:17 UTC |
Dawkins Keith DEVP, Global Chief Med. Off.
|
GrantCommon Stock | 22,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005433 · doc4.xml · nonDerivative · entry 1 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,384 F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2016 and was subject to the completion of the concurrent three-year individual service period. On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 28, 2017 Filed Jan 3, 2019 14:06 UTC Amendment |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
GrantPerformance Share Units · Derivative | 21,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000172 · doc4a.xml · derivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,502 Underlying: Common Stock · 21,502 shares Expires 2018-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F2 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F2 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F2 · balance_after: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| February 28, 2017 Filed Jan 3, 2019 14:05 UTC Amendment |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
GrantPerformance Share Units · Derivative | 23,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000171 · doc4a.xml · derivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,157 Underlying: Common Stock · 23,157 shares Expires 2018-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F2 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F2 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F2 · balance_after: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:59 UTC |
Thepaut Eric Francis YvesSVP & Pres, Europe
|
Exercise / conversionDeferred Stock Units · Derivative | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004955 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,300 shares Expires 2017-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:59 UTC |
Thepaut Eric Francis YvesSVP & Pres, Europe
|
Tax withholdingCommon Stock | 946 | $24.81 | $23,470.26 |
DisclosureSEC source: 0001225208-17-004955 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,300.99 Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:59 UTC |
Thepaut Eric Francis YvesSVP & Pres, Europe
|
Exercise / conversionCommon Stock | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004955 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,246.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:59 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Exercise / conversionDeferred Stock Units · Derivative | 7,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004954 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,166 shares Expires 2017-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:59 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Tax withholdingCommon Stock | 2,398 | $24.81 | $59,494.38 |
DisclosureSEC source: 0001225208-17-004954 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,336 Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:59 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Exercise / conversionCommon Stock | 7,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004954 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:59 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
Exercise / conversionDeferred Stock Units · Derivative | 9,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004953 · doc4.xml · derivative · entry 4 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,915 Underlying: Common Stock · 9,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F4 · balance_after: Reflects multiple DSU awards with independent vesting schedules. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:59 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
SaleCommon Stock | 4,832 | $24.84 | $120,033.64 |
DisclosureSEC source: 0001225208-17-004953 · doc4.xml · nonDerivative · entry 3 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,621 F2 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:59 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
Tax withholdingCommon Stock | 3,305 | $24.81 | $81,997.05 |
DisclosureSEC source: 0001225208-17-004953 · doc4.xml · nonDerivative · entry 2 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,453 Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:59 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
Exercise / conversionCommon Stock | 9,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004953 · doc4.xml · nonDerivative · entry 1 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:58 UTC |
Pierce David ASVP and President, Endoscopy
|
Exercise / conversionDeferred Stock Units · Derivative | 3,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004952 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,185 shares Expires 2017-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:58 UTC |
Pierce David ASVP and President, Endoscopy
|
SaleCommon Stock | 3,417 | $24.84 | $84,883.06 |
DisclosureSEC source: 0001225208-17-004952 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,816 F2 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:58 UTC |
Pierce David ASVP and President, Endoscopy
|
Tax withholdingCommon Stock | 1,034 | $24.81 | $25,653.54 |
DisclosureSEC source: 0001225208-17-004952 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,233 Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:58 UTC |
Pierce David ASVP and President, Endoscopy
|
Exercise / conversionCommon Stock | 3,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004952 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionDeferred Stock Units · Derivative | 57,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004951 · doc4.xml · derivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 26,972 | $24.81 | $669,175.32 |
DisclosureSEC source: 0001225208-17-004951 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,672,443 Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 57,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004951 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,699,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:58 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionDeferred Stock Units · Derivative | 4,618 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004950 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,618 shares Expires 2017-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:58 UTC |
Carruthers WendySVP, Human Resources
|
Tax withholdingCommon Stock | 1,499 | $24.81 | $37,190.19 |
DisclosureSEC source: 0001225208-17-004950 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,992 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:58 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 4,618 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004950 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:57 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionDeferred Stock Units · Derivative | 2,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004949 · doc4.xml · derivative · entry 4 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,548 shares Expires 2017-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:57 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Tax withholdingCommon Stock | 1,178 | $24.81 | $29,226.18 |
DisclosureSEC source: 0001225208-17-004949 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,818 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:57 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionCommon Stock | 2,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004949 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:57 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionDeferred Stock Units · Derivative | 2,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004948 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,588 shares Expires 2017-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:57 UTC |
Brennan Daniel J.EVP and CFO
|
Tax withholdingCommon Stock | 1,218 | $24.81 | $30,218.58 |
DisclosureSEC source: 0001225208-17-004948 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,168 Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:57 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 2,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004948 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionDeferred Stock Units · Derivative | 6,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004926 · doc4.xml · derivative · entry 4 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 6,370 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F5 · balance_after: Reflects multiple DSU awards with independent vesting schedules. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Tax withholdingCommon Stock | 2,068 | $24.81 | $51,307.08 |
DisclosureSEC source: 0001225208-17-004926 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,863 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionCommon Stock | 6,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004926 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionDeferred Stock Units · Derivative | 2,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004925 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,389 shares Expires 2017-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Tax withholdingCommon Stock | 898 | $24.81 | $22,279.38 |
DisclosureSEC source: 0001225208-17-004925 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,782 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 2,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004925 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionDeferred Stock Units · Derivative | 2,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004924 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,389 shares Expires 2017-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 803 | $24.81 | $19,922.43 |
DisclosureSEC source: 0001225208-17-004924 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,938 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 2,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004924 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Fitzgerald Joseph MichaelEVP & President, CRM
|
Exercise / conversionDeferred Stock Units · Derivative | 5,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004923 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,179 Underlying: Common Stock · 5,972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F5 · balance_after: Reflects multiple DSU awards with independent vesting schedules. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Fitzgerald Joseph MichaelEVP & President, CRM
|
Tax withholdingCommon Stock | 2,007 | $24.81 | $49,793.67 |
DisclosureSEC source: 0001225208-17-004923 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,188 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Fitzgerald Joseph MichaelEVP & President, CRM
|
Exercise / conversionCommon Stock | 5,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004923 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.